Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Jan 13;18(1):e0280401. doi: 10.1371/journal.pone.0280401

Electrophysiological properties and heart rate variability of patients with thalassemia major in Jakarta, Indonesia

Rubiana Sukardi 1,*,#, Pustika Amalia Wahidiyat 2,#, Phebe Anggita Gultom 3,#, Mokhammad Ikhsan 4,#, Muhammad Yamin 5,#, Simon Salim 5,#, Mulyadi M Djer 4,#
Editor: Elena G Tolkacheva6
PMCID: PMC9838856  PMID: 36638135

Abstract

Beta thalassemia major (TM) is a common hereditary disease in Indonesia. Iron overload due to regular transfusion may induce myocardial iron deposition leading to electrophysiological dysfunction and functional disorders of the heart. Ventricular arrhythmia is one of the most common causes of sudden cardiac death in thalassemia patients. This cross-sectional study of 62 TM patients aged 10–32 years in Cipto Mangunkusumo General Hospital was done to assess their electrophysiological properties and heart rate variability, including 24- hour Holter monitoring, signal averaged electrocardiogram (SAECG) for detection of ventricular late potential (VLP), and determination of heart rate variability (HRV). We also assessed their 12-lead ECG parameters, such as P wave, QRS complex, QT/ QTc interval, QRS dispersion, and QT/ QTc dispersion. Iron overload was defined by T2-star magnetic resonance (MR-T2*) values of less than 20 ms or ferritin level greater than 2500 ng/mL. Subjects were grouped accordingly. There were significant differences of QTc dispersion (p = 0.026) and deceleration capacity (p = 0.007) between MR-T2* groups. Multivariate analysis showed an inverse correlation between QTc dispersion and MR-T2* values. There was a proportional correlation between heart rate deceleration capacity in the low MR-T2* group (p = 0.058) and the high ferritin group (p = 0.007). No VLPs were detectable in any patients. In conclusion, prolonged QTc dispersion and decreased heart rate deceleration capacity were significantly correlated with greater odds of iron overload among patients with Thalassemia major.

Introduction

Beta thalassemia major (TM) is one of the most common occurrences in hereditary hemoglobinopathy, due to deficiency or absence of β-globin subunits, which leads to ineffective erythropoiesis. Diagnosis of TM is usually determined at the age of 1–2 years [1, 2]. Lifelong blood transfusions, along with extravascular hemolysis and increased intestinal absorption of iron contribute to iron overload in such patients. Consequently, iron chelation therapy is of utmost importance. However, chelation may not be sufficient to prevent overload and iron- related toxicity. The heart is one of the main organs affected by iron toxicity [3, 4]. The proposed mechanisms of TM-related cardiomyopathy include membrane damage by lipid peroxidase, mitochondrial respiratory chain enzyme damage, electrical activity disruptions, cardiac fibrosis, and gene expression alterations. These mechanisms can change both cardiac rhythm and structures [5, 6].

The two most common electrophysiological abnormalities in TM patients are disturbances in cardiac autonomic function and paroxysmal supraventricular tachyarrhythmias such as atrial fibrillation, atrial flutter and intra atrial reentrant tachycardia, while ventricular arrhythmias are manifestation that are more specific due to iron cardiotoxicity [7]. Conventional electrocardiography (ECG) has limited role to assess cardiac autonomic function and ventricular arrhythmia since the majority of patients with asymptomatic cardiomyopathy have normal ECG. Although T2-star magnetic resonance (MR-T2*) has been demonstrated as promising for early diagnosis of iron overload cardiomyopathy, it cannot be used to evaluate cardiac autonomic disturbances or ventricular arrhythmias. Furthermore, its use is also limited by lack of availability and high cost, particularly in low- and middle-income countries.

Recently, Holter monitoring and signal averaged electrocardiogram (SAECG) have been used to determine cardiac autonomic function and ventricular late potential as predictors of ventricular arrhythmias in patients with post-myocardial infarction and heart failure [8, 9]. Despite their clinical significance, there have been a limited number of cross-sectional studies investigating Holter monitoring and SAECG in TM patients [4, 10]. As such, we aimed to compare electrophysiological properties of TM patients with and without iron overload at Cipto Mangunkusumo General Hospital, Jakarta using 24-hour Holter monitoring and SAECG measurements.

Materials and methods

Study protocol

We conducted a cross-sectional study involving 62 TM patients aged 10–32 years at the Pediatric Hematology outpatient clinic in Cipto Mangunkusumo General Hospital, Jakarta. Subjects received regular blood transfusions and various types of iron chelation. Patients with heart failure, acute or chronic inflammatory diseases, metabolic disorders, and those taking anti-arrhythmic and/or cardiovascular medication affecting sympatho-vagal balance in the past 3 months were excluded. The study protocol was reviewed and approved by the institutional ethics committee of the Faculty of Medicine, Universitas Indonesia (No. 19-11-1274). Written informed consent was obtained from all participants or their guardians in the study.

Subjects underwent history-taking, physical examinations, and blood tests. We collected demographic data as well as information on age at diagnosis, drug(s) usage, and blood transfusion frequency. We routinely measured blood pressure and heart rate measurements. The most recent ferritin level and MR-T2* data were evaluated within three months prior to data collection from medical records. Subsequently, patients were grouped according to their ferritin levels as well as their MR-T2* values. Cardiac T2* values of ≥ 20 ms were considered normal. At the time of entry into the study, a 24-hour Holter ECG recording for HRV analysis and SAECG for ventricular late potential were collected.

A 24-hour Holter monitoring assessment

Conduction pattern assessment

We used the Vasomedical-BIOXTM 1306 ultra-compact 12-channel ECG (25 mm/second, amplitude of 10 mm/mV) with silver chloride electrodes. ECG waves were measured using EP Calipers application for Mac. Recordings were done at rest in a quiet room. Parameters used in this study were P wave duration, QRS duration, PR interval, QRS dispersion, QT interval, QTc interval, QT dispersion, and QTc dispersion. P wave interval was measured from the beginning to the end of the P wave. PR interval was measured from the beginning of the P wave to the beginning of Q wave. QRS duration was measured from the beginning of the Q wave to the end of the S wave. QT interval was measured from the beginning of the QRS complex until the end of the T wave, and the end of the T wave was determined by the tangent method. QT interval was corrected for heart rate using Bazett formula (QTc = QT/√R-R interval) [11]. QRS, QT, and QTc dispersion were calculated by subtracting maximum durations of QRS, QT, and QTc in each lead with the minimum durations of QRS, QT, and QTc interval. All the parameters were measured from an average of three consecutive beats, mostly in lead II and V1. QRS, QT, and QTc dispersion were calculated manually. Heart rate deceleration capacity was defined as the expression of extrinsic neural control of the heart to decelerate the rate and measured quantitively using a 24-hour ambulatory electrocardiogram [12, 13].

Heart rate variability

Heart rate variability was measured using Vasomedical-BIOXTM 1306 ultra compact 12-channel ECG 24- hour Holter Recorder. We assessed the following parameters: standard deviation of all normal sinus RR intervals for 24-hour (SDNN), standard deviation of the averaged normal sinus RR intervals in all 5-minute segments (SDANN), root mean square of each successful RR interval difference (rMSSD), the percentage of successive normal sinus RR intervals >50 ms (pNN50), and the percentage of pNN50 [14]. Patients were asked to maintain their daily routine activities during the recording.

Presence of ectopic beat

The presence of ectopic beat, such as premature atrial contraction and ventricular premature beat, was evaluated from a 24-hour Holter recording.

SAECG

We performed Vasomedical BIOXTM 1303 ultra compact 3-channel ECG Holter Recorder for SAECG and silver chloride electrode. Recordings were accepted for analysis if two of the following criteria were met: number of beats averaged >250, and mean noise levels were <1.0 μV for 25 Hz filters or <0.7 μV for 40 Hz filters. SAECG parameters were considered abnormal if total QRS duration was >114 ms, duration of low amplitude signals lower than 40 μV (LAS40) were >38 ms, and root mean square voltage of signals in the last 40 ms of the high frequency QRS intervals (RMS40) were <20 μV [15]. An SAECG study was considered positive for VLPs if two of these three parameters were abnormal, according to previous recommendations [16]. During SAECG assessment, the patient was lying down for fifteen minutes in a quiet room and all metal accessories had been removed.

Statistical analysis

We performed descriptive and analytical statistic using SPSS Statistics 23.0. Continuous data are presented as mean and standard deviation (SD), or median and interquartile range (IQR) values as appropriate. We used independent t-test for normal data distribution and Mann-Whitney test for heterogenous data distribution. A p-value less than 0.05 was statistically significant. Multivariate analysis was performed for parameters with p-values less than 0.2 using linier regression. All parameters were compared between ferritin status groups (< 2500 ng/mL and ≥2500 ng/mL) as well as between MR-T2* status groups (<20 ms and ≥20 ms).

Results

Demographic characteristics

Of 62 subjects, most were in the 16-20-year age group and male (S1 Table). Fifty-seven (91.9%) subjects had high levels of ferritin (≥2500 ng/mL), with 19 (30.6%) of the subjects had MR-T2* values less than 20 ms. Most subjects received deferiprone (61.3%) three times a day for chelation Mean age at first transfusion was 10 months, and mean duration of transfusion was 16.8 years.

Conduction pattern assessment

Forty-nine patients underwent 12-lead ECG (3 refused, 10 were out of reach). QRS duration was wider in the low ferritin group compared to the high ferritin group(85.5 ms vs. 73.4 ms, respectively, p = 0.045). QTc dispersion was also significantly higher in the low MR-T2* group than in the high MR-T2* group, (72 ms vs 53.2 ms, respectively, p = 0.026) (S2 Table) Although both results were statistically significant, there were no differences of cardiac manifestation found between two groups.

Heart rate variability and presence of ectopic beat

On HRV analysis, only heart rate deceleration capacity was lower in the low MR-T2* group than in the high group, (4.1 vs 5.2, respectively, p = 0.007) although there were no important clinical manifestationdifference between two groups (S3 Table).

SAECG

No difference in SAECG parameters were observed between ferritin level groups or MR-T2* groups (S4 Table).

Multivariate analysis

Both QTc dispersion and heart rate deceleration capacity were associated with MR-T2* status (S5 Table). Patients with lower QTc dispersion had a greater likelihood of high MR-T2* level, as did those with higher heart rate deceleration capacity.

Discussion

This study explored the relationship of electrophysiological properties and heart rate variability with iron overload in 62 patients with thalassemia major in Indonesia. The results indicate that prolonged QTc dispersion and decreased heart rate deceleration capacity were significantly correlated with greater odds of iron overload among TM patients.

Serum ferritin level is commonly used to monitor iron concentration in the body, but MR-T2* is still considered to be the gold standard to quantify iron concentration in myocardial tissue [17]. Lower MR-T2* value is a result of higher iron concentration in myocardial tissue. MR-T2* values < 20 ms indicate cardiac siderosis, while MR-T2* values < 10 ms indicate a higher risk of symptomatic heart failure and mortality [18]. Most of our subjects had high serum ferritin level. This finding might have been related to poor compliance to taking chelating drugs, subjective feeling towards the drugs, and lack of drug availability [19]. However, more than 60% of subjects had normal MR-T2* values, possibly because the majority of our patients received deferiprone. Based on previous studies, deferiprone is known to have specific action on cardiac siderosis and is superior to subcutaneous deferoxamine in preventing morbidity and mortality due to cardiac siderosis [2023].

A 12-lead ECG has been used as one of early diagnostic tools for analyzing electrical conduction disturbances [20, 24]. QTc interval is reasonably specific to diagnose iron overload cardiomyopathy. Previous studies revealed that increasing iron stores in men correlated with prolonged QTc interval and may induce cardiac arrhythmias, including torsades de pointes, ventricular fibrillation, and sudden cardiac death [25, 26]. We found no significant differences in QT and QTc intervals between ferritin groups nor between MR-T2* groups. Heart rate- corrected QT intervals were considered prolonged if >450 ms for males and >460 ms for females [27]. Using these definitions, 12.2% of our patients had prolonged QTc. QTc prolongation was found to correlate with iron status (ferritin) and cardiac iron (MR-T2*) [25], but we found no such correlations between QTc and iron status in our study. This observation might have been because subjects’ ferritin or iron status was obtained within three months prior to the study, therefore, the iron status obtained may not have reflected the current or recent condition of the patients.

QT dispersion (QTd) and QTc dispersion are also sensitive for predicting repolarization abnormality. QTc dispersion is one of the surrogate markers for ventricular repolarization homogeneity [28]. Previous studies showed that the prevalence of increased QTc dispersion > 65 ms increased the risk of ventricular arrhythmias [29, 30]. In our study, this condition was found in 31% of patients with high ferritin (vs 50% in the low ferritin group) and in 53% of patients with low MR-T2* (vs 22% in the high MR-T2*).

Previous studies investigated QT parameters in healthy people and TM patients [25, 30, 31]. Demircan et al. and Kayrak et al. reported prolonged P waves, QT and T peak-to-end dispersions, T peak-to-end intervals, and increased T peak-to-end/QT ratios, regardless of MR-T2* status [31, 32]. In addition, Najib et al. reported prolonged QTc interval in subjects with MR-T2* values < 20 ms [25]. Our results were in general agreement with reports by Demircan et al. and Kayrak et al., who showed no relationship between QT parameters and MR-T2* and ferritin level, except for QTc dispersion, which was prolonged in the MR-T2* <20ms group [31, 32].

To the best of our knowledge, studies on HRV assessment in TM patients have been limited. HRV shows changes of autonomic activity and its impact on heart function. TM patients with chronic anemia may have reduced HRV, which subsequently lead to tachycardia and a sustained decrease of autonomic fluctuations [33, 34]. Decreased HRV, even when patients show no symptoms, correlates with regional wall motion abnormality [35].

In our study, there were no statistically significant differences in all HRV parameters between ferritin groups and between MR-T2* groups. However, a comparison to HRV data based on age in normal subjects revealed that the HRV of our TM patients was below the normal range [14]. Heart rate deceleration capacity in 24 hours is a quantitative evaluation of vagal tone intensity. Reduced deceleration capacity means reduced vagal excitability, which correspondingly downgrades its protection of the human body and increases sudden cardiac death risk [36]. Our low MR-T2* patients and high ferritin level patients had lower deceleration capacity. Multivariate analysis also revealed an inverse correlation between heart rate deceleration capacity and MR-T2* values.

SAECG has been used to assess ventricular tachycardia as the underlying substrate in up to 5% of sudden cardiac deaths among TM patients. VLP measurement is a tool to assess for the presence of low voltage areas in the myocardium, which are mainly caused by infarction. In thalassemia patients, infarction may occur due to chronic anemia and iron deposits in the myocardium. The prevalence of VLP among the TM population varies between 3–31% [37, 38].

Contrary to those studies, none of our patients had detectable VLP using SAECG. We also found no correlation of myocardial iron concentration, as reflected by MR-T2*, with the existence of VLP based on SAECG. Late gadolinium enhancement CMR examination may be done to evaluate fibrotic areas in myocardial tissue, but it is very expensive, invasive, and has limited availability [39]. Based on this study, we cannot propose SAECG as a routine screen for early diagnosis of ventricular arrhythmia, however, a simple examination such as electrocardiography to determine prolonged QTc interval and QTc dispersion might be sensitive enough to predict early ventricular arrhythmia.

There were several limitations to this study. First, MR-T2* examination was not performed in conjunction with the electrocardiography study. There was a one-year gap between MR-T2* examination and the start of this study. We did not repeat MR-T2* due to limited funds. However, according to previous studies, MR- T2* data would not differ much within a year [40, 41]. Second, the number of participants in the ferritin groups were not balanced, as it was difficult to find subjects with ferritin levels <2500 ng/ml because of their compliance in taking chelating drugs. As such, medication adherence needs to be monitored. A prospective cohort study is needed for further investigation.

Conclusions

In our study, prolonged QTc dispersion and decreased heart rate deceleration capacity correlate with low MR- T2* as a reliable marker for myocardial iron deposition.

Supporting information

S1 Table. Demographic characteristics of patients with thalassemia major.

(DOCX)

S2 Table. Conduction patterns in the ferritin and MR-T2*.

(DOCX)

S3 Table. Heart rate variability performance in the ferritin and MR-T2* groups.

(DOCX)

S4 Table. SAECG measurements in the ferritin and MR-T2* groups.

(DOCX)

S5 Table. Multivariate analysis between MR-T2* values and electrophysiological properties.

(DOCX)

S1 Dataset

(XLSX)

Data Availability

All relevant data are contained within the manuscript and its Supporting Information files.

Funding Statement

This research was supported by a Universitas Indonesia Research Grant, with internationally indexed [grant number NKB-1574/UN2.RST/HKP.05.00/2020], received by PAW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the B thalassemias. Cold Spring Harb Perspect Med 2012;2:(a011726). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128:281–308. [DOI] [PubMed] [Google Scholar]
  • 3.Kolios M, Korantzopoulos P, Vlahos AP, Kapsali E, Briasoulis E, Goudevenos JA. Electrocardiographic abnormalities and arrhythmic risk markers in adult patients with beta thalassemia major. Int J Cardiol 2016;221:932–6. doi: 10.1016/j.ijcard.2016.07.037 [DOI] [PubMed] [Google Scholar]
  • 4.Oztarhan K, Delibas Y, Salcioglu Z, Kaya G, Bakari S, Bornaun H, et al. Assessment of cardiac parameters in evaluation of cardiac functions in patients with thalassemia major. Pediatr Hematol Oncol 2012;29:220–34. doi: 10.3109/08880018.2012.671449 [DOI] [PubMed] [Google Scholar]
  • 5.Berdoukas V, Coates TD, Cabantchik ZI. Iron and oxidative stress in cardiomyopathy in thalassemia. Free Radic Biol Med 2015;88:3–9. doi: 10.1016/j.freeradbiomed.2015.07.019 [DOI] [PubMed] [Google Scholar]
  • 6.Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol 2009;25:213–8. doi: 10.1016/s0828-282x(09)70064-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Russo V, Rago A, Papa AA, Nigro G. Electrocardiographic presentation, cardiac arrhythmias and their management in b-thalassemia major patients. Ann Noninvasive Electrocardiol 2016;21(4):335–42 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Romberg D, Langel J, Theres H, Kohlstrung P, Bethge K, Stangl K, et al. Correlations between SAECG and HRV parameters in individual patients after myocardial infarction. Comput Cardio 1996;l0:321–3. [Google Scholar]
  • 9.Patel VN, Pierce BR, Bodapati RK, Brown DL, Ives DG, Stein PK. Association of Holter-derived heart rate variability parameters with the development of congestive heart failure in the Cardiovascular Health Study. JACC Heart Fail 2017;5:423–31. doi: 10.1016/j.jchf.2016.12.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Postema PG, Wilde AAM. The measurement of QT interval. Curr Cardiol Rev. 2014;10(3):287–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Franzoni F, Galetta F, Di Muro C, Buti G, Pentimone F, Santoro G. Heart rate variability and ventricular late potentials in β-thalassemia major. Haematologica 2004;89:233–4. [PubMed] [Google Scholar]
  • 12.Hu W, Jin X, Zhang P, Yu Q, Yin G, Lu Y, et al. Deceleration and acceleration capacities of heart rate associated with heart failure with high discriminating performance. Sci Rep 2016;6:23617. doi: 10.1038/srep23617 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Arsenos P, Manis G. Deceleration capacity of heart rate: two new methods of computation. Biomed Signal Process Control 2014;14:158–63. [Google Scholar]
  • 14.Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: Relations to age and gender over nine decades. J Am Coll Cardiol 1998;31:593–601. doi: 10.1016/s0735-1097(97)00554-8 [DOI] [PubMed] [Google Scholar]
  • 15.Gatzoulis KA, Arsenos P, Trachanas K, Dilaveris P, Antoniou C, Tsiachris D, et al. Signal-averaged electrocardiography: past, present, and future. J Arrhythm 2018;34:222–9. doi: 10.1002/joa3.12062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rejdak K, Rubaj A, Głowniak A, Furmanek K, Kutarski A, Wysokiński A, et al. Analysis of ventricular late potentials in signal-averaged ECG of people with epilepsy. Epilepsia 2011; 52:2118–24. doi: 10.1111/j.1528-1167.2011.03270.x [DOI] [PubMed] [Google Scholar]
  • 17.Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. Maedica (Bucur) 2013;8:328–32. [PMC free article] [PubMed] [Google Scholar]
  • 18.Taher AT, Saliba AN, Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program 2017:265–71. doi: 10.1182/asheducation-2017.1.265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wahidiyat PA, Sari TT, Rahmartani LD, Setianingsih I, Iskandar SD, Pratanata AM, et al. An insight into Indonesian current thalassaemia care and challenges. ISBT Sci Ser 2015;15(3):334–41 [Google Scholar]
  • 20.Detterich J, Noetzli L, Dorey F, Bar-cohen Y, Harmatz P, Coates T, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol 2012;87:139–44. doi: 10.1002/ajh.22205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Musallam KM, Taher AT. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica 2011;96(2):5–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011;96(1):41–7. doi: 10.3324/haematol.2009.019042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009;42(3):247–51. doi: 10.1016/j.bcmd.2009.01.002 [DOI] [PubMed] [Google Scholar]
  • 24.Faruqi A, Amjad S, Sami AN, Hassan S, Zia Q. Electrocardiographic changes in thalassemia major patients and their association with serum ferritin levels. JRMC 2015;19(3):185–8. [Google Scholar]
  • 25.Henriksen LF, Petri AS, Hasselbalch HC, Kanters JK, Ellervik C. Increased iron stores prolong the QT interval–a general population study including 20 261 individuals and meta-analysis of thalassaemia major. Br J Haematol 2016;174(5):776–85. [DOI] [PubMed] [Google Scholar]
  • 26.Advani N, Advani N, Andriastuti M. The corrected QT interval prolongation in adolescents with cardiac iron overload β-thalassemia major. Turk J Pediatr 2020;62(2):267–73. [DOI] [PubMed] [Google Scholar]
  • 27.Sandau KE, Funk M, Auerbach A, Barsness GW, Blum K, Cvach M, et al. Update to Practice Standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. Circulatio 2017;136(19):e273–344. doi: 10.1161/CIR.0000000000000527 [DOI] [PubMed] [Google Scholar]
  • 28.Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. Circulation 1999;100(6):675–83. [DOI] [PubMed] [Google Scholar]
  • 29.Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994;5(8):672–85. doi: 10.1111/j.1540-8167.1994.tb01190.x [DOI] [PubMed] [Google Scholar]
  • 30.Surawicz B. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol. 1996;7(8):777–84. doi: 10.1111/j.1540-8167.1996.tb00583.x [DOI] [PubMed] [Google Scholar]
  • 31.Demircan T, Onder Sivis Z, Tatlı Güneş B, Karadeniz C. Evaluation of electrocardiographic markers of cardiac arrhythmic events and their correlation with cardiac iron overload in patients with β- thalassemia major. Cardiol Young 2020; 30(11):1666–71. [DOI] [PubMed] [Google Scholar]
  • 32.Kayrak M, Acar K, Gul EE, Özbek O, Abdulhalikov T, Sonmez O, et al. The association between myocardial iron load and ventricular repolarization parameters in asymptomatic beta-thalassemia patients. Adv Hematol 2012:170510. doi: 10.1155/2012/170510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kardelen F, Tezcan G, Akcurin G, Ertug H, Yesilipek A. Heart rate variability in patients with thalassemia major. Pediatr Cardiol 2008;29(5):935–9. doi: 10.1007/s00246-008-9240-1 [DOI] [PubMed] [Google Scholar]
  • 34.Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, et al. Blood pressure and heart rate in young thalassemia major patients. Am J Hypertens 1998;11(5):539–47. doi: 10.1016/s0895-7061(97)00263-x [DOI] [PubMed] [Google Scholar]
  • 35.De Chiara B, Crivellaro W, Sara R, Ruffini L, Parolini M, Fesslovà V, et al. Early detection of cardiac dysfunction in thalassemic patients by radionuclide angiography and heart rate variability analysis. Eur J Haematol 2005;74(6):517–22. doi: 10.1111/j.1600-0609.2005.00434.x [DOI] [PubMed] [Google Scholar]
  • 36.Wang XD, Zhou L, Zhu CY, Chen B, Chen Z, Wei L. Autonomic function as indicated by heart rate deceleration capacity and deceleration runs in type 2 diabetes patients with or without essential hypertension. Clin Interv Aging 2018;13:1169–76. doi: 10.2147/CIA.S149920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Isma’eel H, Shamseddeen W, Taher A, Gharzuddine W, Dimassi A, Alam S, et al. Ventricular late potentials among thalassemia patients. Int J Cardiol 2009;132(3):453–5. doi: 10.1016/j.ijcard.2007.08.103 [DOI] [PubMed] [Google Scholar]
  • 38.Isma’eel H, Taher A, Shamseddeen W, Khoury M, Gharzuddine W, Arnaout MS, et al. SAECG parameters and left ventricular chamber sizes: lesson from anemia conditions in thalassemia major patients. Int J Cardiol 2006;113(3):102–4. doi: 10.1016/j.ijcard.2006.06.019 [DOI] [PubMed] [Google Scholar]
  • 39.Pepe A, Meloni A, Rossi G, Midiri M, Missere M, Valeri G, et al. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. Eur Heart J Cardiovasc Imaging 2018;19(3):299–309. doi: 10.1093/ehjci/jex012 [DOI] [PubMed] [Google Scholar]
  • 40.Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22(23):2171–9. doi: 10.1053/euhj.2001.2822 [DOI] [PubMed] [Google Scholar]
  • 41.Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica 2011;96(1):48–54. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Elena G Tolkacheva

28 Jul 2022

PONE-D-22-13754Electrophysiological Properties and Heart Rate Variability of Patients with Thalassemia Major in Jakarta, Indonesia PLOS ONE

Dear Dr. Sukardi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address all comments indicated by the Reviewers.

Please submit your revised manuscript by Sep 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Elena G. Tolkacheva, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. You indicated that you had ethical approval for your study. In your Methods section, please ensure you have also stated whether you obtained consent from parents or guardians of the minors included in the study or whether the research ethics committee or IRB specifically waived the need for their consent.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors performed clinical investigations in beta-thalassemia patients with iron overload and accessed their cardiac functions using T2 star MRI, EKG, and HRV techniques. I suggest the authors include values of other iron parameters (such as serum iron and total iron-binding capacity) and numbers of blood transfusion units in the demographic data table.

Reviewer #2: The authors evaluated the association of electrophysiological parameters with serum ferritin levels and cardiac T2* values.

The manuscript has several issues that should be amended.

- In the Introduction, you stated that ventricular arrhythmia is one of the commonest electrophysiological abnormalities. In our experience supraventricular arrhythmias are more common than ventricular arrhythmias.

- It is well known that, besides iron levels, other factors can affect serum ferritin measurements (i.e. inflammation). Therefore, you should consider the mean value of serum ferritin levels in the year rather than a single measurement.

- There is no description of cardiac T2* quantification. Please, add it.

- Generally, not-normally distributed data are presented as median and Interquartile range and not as median and minimum and maximum. Please, correct the paper accordingly.

- Use “normal distribution” instead of “homogeneous distribution”.

- The considered patients are not 62. Please correct the text and report the demographic and clinical data of patients effectively considered.

- What do you mean with a “not clinically important difference”?

- You should perform a ROC curve analysis to evaluate if there is a QTc dispersion value that can predict iron overload with acceptable sensitivity and specificity.

- Which type of multivariate analysis did you perform? Please clarify. Where are the results of the univariate analysis?

- Any data about dose and frequency of chelators? At least partial information about compliance? You have really many patients with increased serum ferritin levels, but also a frequency of myocardial iron of 30% is not low……

- The Discussion needs to be shortened.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-22-13754.pdf

Decision Letter 1

Elena G Tolkacheva

28 Dec 2022

Electrophysiological Properties and Heart Rate Variability of Patients with Thalassemia Major in Jakarta, Indonesia

PONE-D-22-13754R1

Dear Dr. Sukardi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Elena G. Tolkacheva, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I have no additional comments. The authors have addressed all my issues and significantly improved the manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Elena G Tolkacheva

5 Jan 2023

PONE-D-22-13754R1

Electrophysiological properties and heart rate variability of patients with thalassemia major in Jakarta, Indonesia

Dear Dr. Sukardi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Elena G. Tolkacheva

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Demographic characteristics of patients with thalassemia major.

    (DOCX)

    S2 Table. Conduction patterns in the ferritin and MR-T2*.

    (DOCX)

    S3 Table. Heart rate variability performance in the ferritin and MR-T2* groups.

    (DOCX)

    S4 Table. SAECG measurements in the ferritin and MR-T2* groups.

    (DOCX)

    S5 Table. Multivariate analysis between MR-T2* values and electrophysiological properties.

    (DOCX)

    S1 Dataset

    (XLSX)

    Attachment

    Submitted filename: PONE-D-22-13754.pdf

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are contained within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES